Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification

13 novembre 2026 mis à jour par: Yinyan Wang, Beijing Tiantan Hospital

Prospective Observational Validation of a Vision-Based Model for Integrated Histopathological and Molecular Classification of Gliomas From Intraoperative Specimen Photographs

This prospective observational cohort study will evaluate the diagnostic performance and workflow feasibility of a prespecified locked artificial intelligence model that analyzes smartphone-based natural-light gross images of fresh surgical tissue together with participant age. Approximately 400 consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will be enrolled at Beijing Tiantan Hospital, Capital Medical University, between July and September 2026. Images will be acquired before frozen-section processing according to a standardized operating procedure. Model outputs will be generated in silent mode and will not be shown to the surgical or pathology teams and will not alter diagnosis or treatment. The locked model score will be compared with the final IDH mutation reference standard derived from permanent histopathology, immunohistochemistry, and indicated molecular testing. The primary objective is to estimate patient-level discrimination for IDH-mutant versus IDH-wildtype tumors. Secondary objectives include fixed-threshold performance, precision-recall performance, calibration, end-to-end technical success, and prespecified model abstention, if an abstention rule is locked before enrollment.

Aperçu de l'étude

Description détaillée

Eligible participants will be enrolled consecutively, and a screening log will document all exclusions. Fresh ex vivo tumor tissue will be photographed before freezing. Images will be deidentified and linked through a participant-surgery-specimen-image hierarchy. The locked SNAP-IDH model will segment the tumor region of interest, permit blinded quality confirmation or editing, and combine frozen iBOT image features with age using a radial basis function support vector machine. The output is a research model score rather than a clinically calibrated absolute risk. A score of frozen yoden or will be classified as IDH-mutant. Model outputs will remain hidden from all clinical decision makers. No retraining, hyperparameter tuning, threshold selection, or recalibration will use the prospective cohort. Diagnostic accuracy will be analyzed at the participant level. Image-acquisition, segmentation, inference, and reference-standard failures will be retained in the study flow and reported separately from complete-case diagnostic performance.

Type d'étude

Observationnel

Inscription (Estimé)

100

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine
        • Recrutement
        • Beijing Tiantan Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Consecutive adults undergoing initial surgery for suspected intracranial adult diffuse glioma at the participating facility

La description

Inclusion Criteria

  1. Adults aged 18 years or older at enrollment.
  2. A newly presenting intracranial lesion is radiologically suspected to be an adult-type diffuse glioma, and the participant is scheduled to undergo initial surgical resection or biopsy at a participating site.
  3. The planned index surgery includes an attempt to collect fresh tumor tissue for standardized natural-light gross-image acquisition before freezing.
  4. Participants must be able and willing to provide written informed consent before any study-specific procedure.

Exclusion Criteria

  1. Two or more radiologically distinct intracranial lesions identified on preoperative imaging.
  2. Radiotherapy or chemotherapy directed at the current intracranial lesion before the index surgery.
  3. Known recurrent disease or a previous tumor-directed surgical procedure for the current lesion.
  4. Primary spinal cord tumor, including a cervical spinal cord tumor.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Prospective Silent-Validation Cohort. Consecutive adults undergoing initial surgery for suspected i

Consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will undergo standardized research imaging of fresh surgical tissue. Locked model outputs will not influence routine surgery, frozen-section assessment, permanent pathology, molecular testing, or treatment.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Patient-Level Area Under the Precision-Recall Curve of the Locked SNAP-IDH Score for IDH Mutation Status
Délai: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Area under the precision-recall curve (AUPRC) calculated using one locked SNAP-IDH score per patient and the final reference-standard isocitrate dehydrogenase (IDH) mutation status, with IDH-mutant status as the positive class. AUPRC ranges from 0 to 1, with higher values indicating better performance.

From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Patient-Level Sensitivity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Délai: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-mutant status classified as IDH-mutant by SNAP-IDH at the prespecified, locked classification threshold. Sensitivity is calculated as true positives divided by the sum of true positives and false negatives, multiplied by 100.

From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
Patient-Level Specificity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Délai: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-wildtype status classified as IDH-wildtype by SNAP-IDH at the prespecified, locked classification threshold. Specificity is calculated as true negatives divided by the sum of true negatives and false positives, multiplied by 100.

From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
Patient-Level Brier Score of the Locked SNAP-IDH Predicted Probability for IDH Mutation Status
Délai: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Mean squared difference between each patient's locked SNAP-IDH predicted probability of isocitrate dehydrogenase (IDH) mutation and the final reference-standard status, coded as 1 for IDH-mutant and 0 for IDH-wildtype. The Brier score ranges from 0 to 1, with lower values indicating lower prediction error.

From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 juillet 2026

Achèvement primaire (Estimé)

30 novembre 2026

Achèvement de l'étude (Estimé)

30 novembre 2026

Dates d'inscription aux études

Première soumission

8 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner